4//SEC Filing
Lorrain Daniel S. 4
Accession 0001437749-26-000616
CIK 0001855175other
Filed
Jan 5, 7:00 PM ET
Accepted
Jan 6, 4:16 PM ET
Size
7.8 KB
Accession
0001437749-26-000616
Insider Transaction Report
Form 4
Lorrain Daniel S.
Chief Scientific Officer
Transactions
- Sale
Class A Common Stock
2026-01-05$10.35/sh−3,670$37,978→ 160,722 total - Sale
Class A Common Stock
2026-01-05$11.13/sh−500$5,565→ 160,222 total
Holdings
- 6,842(indirect: By Spouse)
Class A Common Stock
Footnotes (3)
- [F1]These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.000 to $10.955, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.00 to $11.34, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
Documents
Issuer
Contineum Therapeutics, Inc.
CIK 0001855175
Entity typeother
Related Parties
1- filerCIK 0001861550
Filing Metadata
- Form type
- 4
- Filed
- Jan 5, 7:00 PM ET
- Accepted
- Jan 6, 4:16 PM ET
- Size
- 7.8 KB